Related Experiment Videos
Bone marrow transplantation for chronic myelogenous leukemia
F R Appelbaum1, R Clift, J Radich
1Fred Hutchinson Cancer Research Center, Seattle, WA 98104-2092, USA.
Seminars in Oncology
|August 1, 1995
Summary
Newly diagnosed chronic myeloid leukemia (CML) patients aged 65 or less should undergo staging and human lymphocyte antigen (HLA) typing. Early consideration for bone marrow transplantation (BMT) is recommended for eligible patients, with donor searches initiated for those without matches.
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Treatment decisions for CML require careful consideration of patient age, disease stage, and donor availability.
Purpose of the Study:
- To provide evidence-based recommendations for the management of newly diagnosed CML patients.
- To outline optimal strategies for considering bone marrow transplantation (BMT) in CML management.
Main Methods:
- Evaluation of patient age, disease stage, and human lymphocyte antigen (HLA) typing.
- Assessment of matched sibling donor availability for BMT.
- Initiation of unrelated donor searches for eligible patients.
Main Results:
- Patients ≤55 years with matched or mismatched siblings should pursue BMT promptly.
- Patients ≤65 years in good health may be considered for early BMT.
- Patients ≤55 years without family donors should have unrelated donor searches initiated.
Conclusions:
- Timely HLA typing and staging are crucial for newly diagnosed CML patients.
- Bone marrow transplantation (BMT) is a key therapeutic option for eligible CML patients.
- Clinical trials for autologous BMT or other approaches should be considered for patients lacking suitable donors.